Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AMIPREP 2
2024-516239-28-00Phase 2Authorised
- Sponsor
- Assistance Publique–Hôpitaux de Marseille
- Start
- Sep 2024
- Modality
- Cell Therapies, Adoptive Cell Transfer → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial of autologous microfat and autologous platelet-rich plasma in wrist osteoarthritis (2 arms), sponsored by Assistance Publique–Hôpitaux de Marseille. Primary endpoint: Pain intensity on visual analog scale (VAS). Planned start Sep 2024; status: authorised.
02
Drugs
autologous microfatautologous platelet-rich plasma
03
Conditions
wrist osteoarthritis
Beyond the preview
Go deeper on 2024-516239-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-516239-28-00.